OmniPf Plus One Ferry Injection

Adult dosage

The dosage and infusion rate are determined according to the patient's fat removal capacity, nitrogen and glucose metabolism capabilities, and nutritional needs, and the dosage and size of the bag are established based on the patient's status and weight. - For patients with normal nutritional status or mild metabolic stress: 0.10-0.15 g/kg of nitrogen per day (as amino acids: 0.6-0.9 g/kg) - For patients undergoing moderate to severe metabolic stress regardless of nutritional imbalance: 0.15-0.25 g/kg of nitrogen per day (as amino acids: 0.9-1.6 g/kg) In very special cases (e.g., burns or marked anabolic states), nitrogen requirements may be even higher. Dosage 1 day of 19-38 mL/kg corresponds to nitrogen 0.10-0.20 g/kg (amino acids 0.6-1.2 g/kg) and total calories 13-26 kcal/kg (non-protein calories 11-21 kcal/kg). This satisfies the needs of most patients. In obese patients, dosing should be based on predicted normal body weight. Administration Rate The administration rate must not exceed 3.0 mL/kg per hour (corresponding to glucose 0.21 g/kg, amino acids 0.10 g/kg, fats 0.08 g/kg per hour). It is desirable to administer the medication over a period of 14-24 hours. Maximum Daily Dosage The maximum daily dosage varies depending on the patient's clinical condition and may change daily. The recommended maximum daily dosage is 40 mL/kg. This recommended maximum daily dosage of 40 mL/kg provides nitrogen 0.21 g/kg (amino acids 1.3 g/kg), glucose 2.8 g/kg, fats 1.1 g/kg, and total calories 28 kcal/kg (corresponding to 23 kcal/kg as non-protein calories). Administration Method Infuse intravenously via peripheral or central vein. Pediatric Patients Use in pediatric patients is not recommended.

Children's dosage

Use in pediatric patients is not recommended.

This medication must be used strictly under the supervision of a physician and should not be taken or discontinued arbitrarily. If allergic reactions such as fever, chills, rash, or difficulty breathing occur during treatment with this medication, discontinue immediately and consult with medical personnel. Do not mix this medication with intravenous drugs containing calcium; if the same infusion equipment must be used, clean the infusion line thoroughly before and after administration. Particularly in premature or low-birth-weight infants, caution is required as the lipid components of this medication may cause problems in the lungs. Patients with allergies to fish, eggs, soybeans, peanuts, or those with specific liver, kidney, or blood disorders should not use this medication. Patients with severe hyperlipidemia, acute shock, or uncontrolled hyperglycemia should also avoid administration. Patients with severely impaired kidney function or unstable conditions such as acute myocardial infarction or stroke should use this medication cautiously. During administration, blood tests and clinical conditions should be monitored frequently to observe for side effects or adverse reactions, particularly closely monitoring blood triglyceride levels. In cases of overdose, symptoms such as nausea, vomiting, hyperglycemia, and fat overload syndrome may appear, requiring adjustments to the administration rate or discontinuation; if necessary, appropriate treatment should be provided. This medication contains ingredients that may cause allergic reactions, so patients with a history of allergies should exercise caution. The safety of this medication in pregnant or lactating women has not been established; it should be decided carefully after consulting a physician if necessary. During administration, ensure thorough aseptic technique to reduce the risk of infection and confirm that the drug is uniformly mixed prior to administration. This medication should be stored at temperatures between 1 and 25 degrees Celsius, and should be used as soon as possible after mixing.

Serious side effects

Anaphylactic reactions (fever, chills, rash, difficulty breathing), cases of death due to fat accumulation in the pulmonary vasculature, symptoms of fat overload syndrome (high fever, jaundice, signs of liver dysfunction), thrombophlebitis, blood coagulation disorders, emergencies due to hyperglycemia, pulmonary edema, heart failure, severe allergic reactions, severe edema, liver problems (jaundice), serious neurological symptoms (confusion, seizures), respiratory problems (difficulty breathing, ...

Mild side effects

Gastrointestinal disturbances (flatulence, constipation, nausea), vascular disturbances (phlebitis), general disturbances (fever, swelling, and pain at the injection site), respiratory thoracic and mediastinal disturbances (pleural effusion, atelectasis), neurological disturbances (headache, sensory loss), musculoskeletal disturbances (back pain), falls, increased bilirubin in the blood, hypophosphatemia, insomnia, nausea, vomiting, chills, sweating, elevated body temperature, hyperglycemia.

This medication should be stored in a sealed container to prevent air and moisture ingress and is best kept at room temperature between 1 and 25 degrees Celsius. This helps maintain the drug's efficacy and prevents degradation.

Appearance

It consists of a transparent, colorless injection solution with three compartments divided by a plastic internal bag and an outer package, with an oxygen absorbent in between. Each compartment contains a transparent and colorless to pale yellow amino acid solution.

Package unit

362 mL/bag [A Solution 114 mL, B Solution 197 mL, C Solution 51 mL], 500 mL/bag [A Solution 157.5 mL, B Solution 272 mL, C Solution 70.5 mL], 724 mL/bag [A Solution 228 mL, B Solution 394 mL, C Solution 102 mL], 952 mL/bag [A Solution 300 mL, B Solution 518 mL, C Solution 134 mL], 1448 mL/bag [A Solution 456 mL, B Solution 788 mL, C Solution 204 mL]